
    
      An interventional, double-blind, randomized, placebo-control design will be used to test
      safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in 70 subjects â‰¥ 18 and < 65
      years of age with documented cystic fibrosis. There will up a screening period of up to 28
      days, 84 days treatment period, and 28 days follow-up.
    
  